Reuters: Global Markets: FDA rejects Repligen's imaging agent, shares drop

Reuters: Global Markets Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

FDA rejects Repligen's imaging agent, shares drop Jun 22nd 2012, 14:02 Fri Jun 22, 2012 10:02am EDT (Reuters) - Repligen Corp said U.S. health regulators denied approval for its imaging agent to detect structural abnormalities in the pancreas, sending its shares down 10 percent. The U.S. Food and Drug Administration has asked for additional efficacy and safety trial data to approve the agent, called RG1068, in a complete response letter. Repligen said in April that it did not expect the FDA to approve the imaging agent as the regulator had canceled an advisory committee meeting to review the agent. In the complete response letter, the regulator did not cite any deficiency with respect to the manufacturing, pharmacology or toxicology sections of the approval application. The company's shares, which dropped 40 percent on April 26 when the company said it was expecting a rejection, were down 9 percent at $3.99 in morning trade on the Nasdaq. They touched a low of $3.95 earlier in the session.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions